Cardioprotection by controlling hyperamylinemia in a "Humanized" diabetic rat model

Sanda Despa, Savita Sharma, Todd R. Harris, Hua Dong, Ning Li, Nipavan Chiamvimonvat, Heinrich Taegtmeyer, Kenneth B. Margulies, Bruce D. Hammock, Florin Despa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background-Chronic hypersecretion of the pancreatic hormone amylin is common in humans with obesity or prediabetic insulin resistance and induces amylin aggregation and proteotoxicity in the pancreas. We recently showed that hyperamylinemia also affects the cardiovascular system. Here, we investigated whether amylin aggregates interact directly with cardiac myocytes and whether controlling hyperamylinemia protects the heart. Methods and Results-By Western blot, we found abundant amylin aggregates in lysates of cardiac myocytes from obese patients, but not in controls. Aggregated amylin was elevated in failing hearts, suggesting a role in myocyte injury. Using rats overexpressing human amylin in the pancreas (HIP rats) and control myocytes incubated with human amylin, we show that amylin aggregation at the sarcolemma induces oxidative stress and Ca<sup>2+</sup> dysregulation. In time, HIP rats developed cardiac hypertrophy and leftventricular dilation. We then tested whether metabolites with antiaggregation properties, such as eicosanoid acids, limit myocardial amylin deposition. Rats were treated with an inhibitor of soluble epoxide hydrolase, the enzyme that degrades endogenous eicosanoids. Treatment doubled the blood concentration of eicosanoids, which drastically reduced incorporation of aggregated amylin in cardiac myocytes and blood cells, without affecting pancreatic amylin secretion. Animals in the treated group showed reduced cardiac hypertrophy and left-ventricular dilation. The cardioprotective mechanisms included the mitigation of amylininduced cardiac oxidative stress and Ca<sup>2+</sup> dysregulation. Conclusions-The results suggest blood amylin as a novel therapeutic target in diabetic heart disease and elevating blood levels of antiaggregation metabolites as a pharmacological strategy to reduce amylin aggregation and amylin-mediated cardiotoxicity.

Original languageEnglish (US)
Article numbere001015
JournalJournal of the American Heart Association
Volume3
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Islet Amyloid Polypeptide
Eicosanoids
Cardiac Myocytes
Cardiomegaly
Muscle Cells
Dilatation
Pancreas
Oxidative Stress
Pancreatic Hormones
Epoxide Hydrolases
Sarcolemma
Cardiovascular System

Keywords

  • Amyloid
  • Calcium
  • Circulation
  • Diabetes mellitus
  • Heart diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardioprotection by controlling hyperamylinemia in a "Humanized" diabetic rat model. / Despa, Sanda; Sharma, Savita; Harris, Todd R.; Dong, Hua; Li, Ning; Chiamvimonvat, Nipavan; Taegtmeyer, Heinrich; Margulies, Kenneth B.; Hammock, Bruce D.; Despa, Florin.

In: Journal of the American Heart Association, Vol. 3, No. 4, e001015, 2014.

Research output: Contribution to journalArticle

Despa, S, Sharma, S, Harris, TR, Dong, H, Li, N, Chiamvimonvat, N, Taegtmeyer, H, Margulies, KB, Hammock, BD & Despa, F 2014, 'Cardioprotection by controlling hyperamylinemia in a "Humanized" diabetic rat model', Journal of the American Heart Association, vol. 3, no. 4, e001015. https://doi.org/10.1161/JAHA.114.001015
Despa, Sanda ; Sharma, Savita ; Harris, Todd R. ; Dong, Hua ; Li, Ning ; Chiamvimonvat, Nipavan ; Taegtmeyer, Heinrich ; Margulies, Kenneth B. ; Hammock, Bruce D. ; Despa, Florin. / Cardioprotection by controlling hyperamylinemia in a "Humanized" diabetic rat model. In: Journal of the American Heart Association. 2014 ; Vol. 3, No. 4.
@article{b3ffdf6dbe7f4170ad9d4c022cba4dc0,
title = "Cardioprotection by controlling hyperamylinemia in a {"}Humanized{"} diabetic rat model",
abstract = "Background-Chronic hypersecretion of the pancreatic hormone amylin is common in humans with obesity or prediabetic insulin resistance and induces amylin aggregation and proteotoxicity in the pancreas. We recently showed that hyperamylinemia also affects the cardiovascular system. Here, we investigated whether amylin aggregates interact directly with cardiac myocytes and whether controlling hyperamylinemia protects the heart. Methods and Results-By Western blot, we found abundant amylin aggregates in lysates of cardiac myocytes from obese patients, but not in controls. Aggregated amylin was elevated in failing hearts, suggesting a role in myocyte injury. Using rats overexpressing human amylin in the pancreas (HIP rats) and control myocytes incubated with human amylin, we show that amylin aggregation at the sarcolemma induces oxidative stress and Ca2+ dysregulation. In time, HIP rats developed cardiac hypertrophy and leftventricular dilation. We then tested whether metabolites with antiaggregation properties, such as eicosanoid acids, limit myocardial amylin deposition. Rats were treated with an inhibitor of soluble epoxide hydrolase, the enzyme that degrades endogenous eicosanoids. Treatment doubled the blood concentration of eicosanoids, which drastically reduced incorporation of aggregated amylin in cardiac myocytes and blood cells, without affecting pancreatic amylin secretion. Animals in the treated group showed reduced cardiac hypertrophy and left-ventricular dilation. The cardioprotective mechanisms included the mitigation of amylininduced cardiac oxidative stress and Ca2+ dysregulation. Conclusions-The results suggest blood amylin as a novel therapeutic target in diabetic heart disease and elevating blood levels of antiaggregation metabolites as a pharmacological strategy to reduce amylin aggregation and amylin-mediated cardiotoxicity.",
keywords = "Amyloid, Calcium, Circulation, Diabetes mellitus, Heart diseases",
author = "Sanda Despa and Savita Sharma and Harris, {Todd R.} and Hua Dong and Ning Li and Nipavan Chiamvimonvat and Heinrich Taegtmeyer and Margulies, {Kenneth B.} and Hammock, {Bruce D.} and Florin Despa",
year = "2014",
doi = "10.1161/JAHA.114.001015",
language = "English (US)",
volume = "3",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Cardioprotection by controlling hyperamylinemia in a "Humanized" diabetic rat model

AU - Despa, Sanda

AU - Sharma, Savita

AU - Harris, Todd R.

AU - Dong, Hua

AU - Li, Ning

AU - Chiamvimonvat, Nipavan

AU - Taegtmeyer, Heinrich

AU - Margulies, Kenneth B.

AU - Hammock, Bruce D.

AU - Despa, Florin

PY - 2014

Y1 - 2014

N2 - Background-Chronic hypersecretion of the pancreatic hormone amylin is common in humans with obesity or prediabetic insulin resistance and induces amylin aggregation and proteotoxicity in the pancreas. We recently showed that hyperamylinemia also affects the cardiovascular system. Here, we investigated whether amylin aggregates interact directly with cardiac myocytes and whether controlling hyperamylinemia protects the heart. Methods and Results-By Western blot, we found abundant amylin aggregates in lysates of cardiac myocytes from obese patients, but not in controls. Aggregated amylin was elevated in failing hearts, suggesting a role in myocyte injury. Using rats overexpressing human amylin in the pancreas (HIP rats) and control myocytes incubated with human amylin, we show that amylin aggregation at the sarcolemma induces oxidative stress and Ca2+ dysregulation. In time, HIP rats developed cardiac hypertrophy and leftventricular dilation. We then tested whether metabolites with antiaggregation properties, such as eicosanoid acids, limit myocardial amylin deposition. Rats were treated with an inhibitor of soluble epoxide hydrolase, the enzyme that degrades endogenous eicosanoids. Treatment doubled the blood concentration of eicosanoids, which drastically reduced incorporation of aggregated amylin in cardiac myocytes and blood cells, without affecting pancreatic amylin secretion. Animals in the treated group showed reduced cardiac hypertrophy and left-ventricular dilation. The cardioprotective mechanisms included the mitigation of amylininduced cardiac oxidative stress and Ca2+ dysregulation. Conclusions-The results suggest blood amylin as a novel therapeutic target in diabetic heart disease and elevating blood levels of antiaggregation metabolites as a pharmacological strategy to reduce amylin aggregation and amylin-mediated cardiotoxicity.

AB - Background-Chronic hypersecretion of the pancreatic hormone amylin is common in humans with obesity or prediabetic insulin resistance and induces amylin aggregation and proteotoxicity in the pancreas. We recently showed that hyperamylinemia also affects the cardiovascular system. Here, we investigated whether amylin aggregates interact directly with cardiac myocytes and whether controlling hyperamylinemia protects the heart. Methods and Results-By Western blot, we found abundant amylin aggregates in lysates of cardiac myocytes from obese patients, but not in controls. Aggregated amylin was elevated in failing hearts, suggesting a role in myocyte injury. Using rats overexpressing human amylin in the pancreas (HIP rats) and control myocytes incubated with human amylin, we show that amylin aggregation at the sarcolemma induces oxidative stress and Ca2+ dysregulation. In time, HIP rats developed cardiac hypertrophy and leftventricular dilation. We then tested whether metabolites with antiaggregation properties, such as eicosanoid acids, limit myocardial amylin deposition. Rats were treated with an inhibitor of soluble epoxide hydrolase, the enzyme that degrades endogenous eicosanoids. Treatment doubled the blood concentration of eicosanoids, which drastically reduced incorporation of aggregated amylin in cardiac myocytes and blood cells, without affecting pancreatic amylin secretion. Animals in the treated group showed reduced cardiac hypertrophy and left-ventricular dilation. The cardioprotective mechanisms included the mitigation of amylininduced cardiac oxidative stress and Ca2+ dysregulation. Conclusions-The results suggest blood amylin as a novel therapeutic target in diabetic heart disease and elevating blood levels of antiaggregation metabolites as a pharmacological strategy to reduce amylin aggregation and amylin-mediated cardiotoxicity.

KW - Amyloid

KW - Calcium

KW - Circulation

KW - Diabetes mellitus

KW - Heart diseases

UR - http://www.scopus.com/inward/record.url?scp=84939460552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939460552&partnerID=8YFLogxK

U2 - 10.1161/JAHA.114.001015

DO - 10.1161/JAHA.114.001015

M3 - Article

C2 - 25146704

AN - SCOPUS:84939460552

VL - 3

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 4

M1 - e001015

ER -